ArticleInternational journal of molecular sciences2026
Rosmarinic Acid Ameliorates Obesity-Associated Metabolic Disturbances and Hepatic Steatosis in Mice with High-Fat Diet-Induced Obesity.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Obesity and obesity-associated hepatic steatosis represent major metabolic health challenges, yet effective pharmacological interventions remain limited. Rosmarinic acid (RA), a natural polyphenol, has been reported to exert anti-obesity effects; however, its specific roles in restoring hepatic lipid homeostasis and modulating glucose metabolism under diet-induced obesity remain unclear. In this study, we investigated the metabolic effects and underlying mechanisms of RA in mice with high-fat diet (HFD)-induced obesity. RA significantly reduced body weight gain and adipose tissue mass without altering total energy intake, accompanied by increased nocturnal energy expenditure and fecal lipid excretion. RA restored hepatic lipid homeostasis by improving circulating lipid profiles and markedly attenuating hepatic steatosis, fibrosis, and hepatocellular injury. These effects were associated with increased fecal lipid excretion, suppression of hepatic lipogenesis, and enhancement of fatty acid oxidation-related markers. Furthermore, RA reduced fasting blood glucose levels and modulated the expression of hepatic glucose metabolism-related genes. Pancreatic immunohistochemistry showed morphological changes in insulin-positive and glucagon-positive cells following RA supplementation. Collectively, these findings indicate that RA ameliorates obesity-associated metabolic disturbances and hepatic steatosis through coordinated regulation of lipid metabolism and hepatic glucose metabolism-related pathways, highlighting its potential relevance for obesity-associated fatty liver conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.